Drug Trial Radar · NCT03478488
Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC
Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
472
Actual
Start
Apr 16, 2018
Primary completion
Sep 10, 2024
Study completion Sep 10, 2024
Sponsor
- Lead sponsor
- 3D Medicines (Sichuan) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 27, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, open-label, parallel-group multi-center study of Phase 3 study to assess the efficacy and safety of KN035 compared to standard of care (SOC) Gemcitabine-based chemotherapies in the treatment of participants with previously untreated locally advanced or metastatic biliary tract cancer. The primary hypothesis of this study is that participants will have a longer overall Survival (OS) when treated with combined therapy than SOC.
Conditions
- Biliary Tract Neoplasms
Interventions
KN035 plus Gemcitabine & oxaliplatinDrug
KN035 a programmed death ligand immune check inhibitor Per Investigator decision
Gemcitabine & oxaliplatinDrug
The standard of care for the patients with unresectable/metastatic biliary tract cancer
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: Observed by 12 weeks after progressive disease or end of treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Chinese people's liberation army (PLA) 81hospital
Nanjing, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.